Provided by Tiger Trade Technology Pte. Ltd.

Sequoia Capital Holdings

3,415.03
+38.611.14%
Number of Gainers:64
Number of Losers:32
Number of Flat:4
PE:- -
High:3,429.07
Open:3,376.52
Low:3,376.52
Close:3,376.42
Volume:1.19B
Turnover:255.31B
Market Cap:44.86T
Float Cap:41.93T

Loading ...

IHG Opens 250-Room Crowne Plaza Paris Marne-La-Vallée Hotel Near Disneyland Paris

Reuters
·
Sep 24

Honeywell Updates Financial Calendar with Quarterly Results Release and Investor Call

Reuters
·
Sep 24

Qualcomm Announces Renewal of Global Patent License Agreement with Apple

THOMSON REUTERS
·
Sep 24

Qualcomm - Announces Renewal of Global Patent License Agreement with Apple Effective April 1, 2027

THOMSON REUTERS
·
Sep 24

Rpt-Qualcomm - Announces Renewal of Global Patent License Agreement with Apple Effective April 1, 2027

THOMSON REUTERS
·
Sep 24

Honeywell Technologies to Release Third Quarter Financial Results and Hold Its Investor Conference Call on Thursday, October 22

THOMSON REUTERS
·
Sep 24

Press Release: Mackenzie Investments Announces September 2026 Distributions for Its Exchange Traded Funds

Dow Jones
·
Sep 24

Intel, Marvell, Super Micro, Meta, MGM, and More Stocks That Explain Today's Market

Dow Jones
·
Sep 24

US 10-Year Treasury Yield Breaks 5%, Testing Corporate Earnings Strength, but JPMorgan Stays Firm: Stocks Will Remain the Portfolio Growth Engine

Stock News
·
Sep 24

Treasury Bond ETFs Hit Multi-Year Lows as Bond Yields Surge

Reuters
·
Sep 24

Merck's Drug for Diabetes-Related Eye Disease Meets Trial Goal

Reuters
·
Sep 24

Amazon Adds Prime Delivery Option, Discounts Fulfillment Fees for Merchants

MT Newswires Live
·
Sep 24

Musk Expands Business Empire Across the American Sun Belt with Massive Investments

Deep News
·
Sep 24

Merck Says Remigromig Meets Primary Endpoint in Pivotal Brunello Trial for Diabetic Macular Edema

Reuters
·
Sep 24

Merck & Co - Higher Rates of Pdr, Vitreous Hemorrhage, and Discontinuations with Remigromig

THOMSON REUTERS
·
Sep 24

Merck’s Remigromig, a Tri-Specific Agonist of the Wingless-Related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2B/3 Brunello Study of Adults with Diabetic Macular Edema

THOMSON REUTERS
·
Sep 24

Merck & Co Inc: Both Doses of Remigromig were Generally Well Tolerated

THOMSON REUTERS
·
Sep 24

Merck & Co - Both Remigromig Doses Show Non-Inferiority to Ranibizumab at 52 Weeks

THOMSON REUTERS
·
Sep 24

Zhaoyang District Apple Industry Drives Rural Revitalization as 2025 Harvest Boosts Comprehensive Output Value to 13.5 Billion Yuan

Deep News
·
Sep 24

Amazon Launches New AI Product, Reflecting Industry-Wide Price Cuts

Deep News
·
Sep 24